acceptodds
Under review as a conference paper at ICLR 2027

Discovering Subgroups with Exceptional Survival Characteristics

Abstract

In many applications, it is important to identify subpopulations that survive longer or shorter than the rest of the population. In medicine, for example, it allows determining which patients benefit from treatment, and in predictive maintenance, which components are more likely to fail. Existing methods for discovering subgroups with exceptional survival characteristics rely on restrictive assumptions about the survival model (e.g. proportional hazards), require pre-discretized features, and, as they compare average statistics, tend to overlook individual heterogeneity. In this paper, we propose Sysurv, a non-parametric, fully differentiable method that discovers human-readable rules selecting subgroups with exceptional survival characteristics. Empirical evaluation on a wide range of datasets and settings, including a case study on cancer data, shows that Sysurv reveals insightful and actionable survival subgroups, outperforming the state of the art.

Primary area:
interpretability and explainable AI
Keywords:
Survival Analysis, Subgroup Discovery, Time-to-Event Data, Interpretability

Reviews

Among:
Shape:
1234this paper, Top 30%
Figure 1. Mean review rating of the reviewed papers at ICLR 2027. This paper averages 2.67 over 3 reviews, above 70% of the others.
Reviewer_LBaxOpenReview ↗
Rating
2
Confidence
1
Informativeness
1
Presentation
2
Soundness
2
Read review
Paper summary

This paper introduces SYSURV, a non-parametric, differentiable framework for discovering interpretable subgroups with unusually high or low survival outcomes. Unlike traditional methods that rely on restrictive modeling assumptions or discretized features, SYSURV captures individual heterogeneity and generates human-readable subgroup rules.

Critical strengths

The paper tackles a practical problem in survival analysis by identifying interpretable subgroups with exceptional survival characteristics. The proposed SYSURV based measure is interesting, particularly its non-parametric and differentiable formulation. The evaluation across multiple datasets, including a real-world cancer case study, helps demonstrate its potential practical relevance.

Critical weaknesses
  1. While the empirical results demonstrate improvements over existing methods, the paper provides limited theoretical justification for why SYSURV should outperform competing approaches. Further analysis of the underlying mechanisms would help strengthen the methodological contributions.

  2. It is not entirely clear whether the main contribution is a novel subgroup discovery method or primarily a new measure for evaluating survival subgroups. The authors should better clarify the methodological novelty and distinguish the proposed approach from existing methods.

Questions for authors
  1. Although the empirical results suggest possible improvements over existing methods, the paper lacks sufficient theoretical analysis explaining why the proposed approach should outperform competing baselines. Does the gain come from the newly propose measure, or this measure combined with typical survival analysis methods? Additional theoretical insights or analysis of the underlying mechanisms would strengthen the methodological contributions.

  2. It is not entirely clear whether the main contribution is a new evaluation measure or a fundamentally new subgroup discovery method. The authors should better clarify the methodological novelty and distinguish SYSURV from existing approaches.

  3. Could the authors clarify whether the figures presented in the paper are generated from real-world experimental results or are primarily illustrative examples?

1 comment

We thank the reviewer for their feedback. A theoretical analysis of our objective and the logrank is included (Appx. J); we made it more explicit (Appx. J, Empirical Analysis, Table 2, Figures 9 and 10), complementing our theoretical guarantees in Appx. E. We address the questions below:

  1. Theoretical and Empirical Justification. The performance advantage stems from two complementary methodological mechanisms:

    • Theoretical advantage under crossing curves and delayed tails (Appx. J, Appx. E): The logrank test evaluates signed differences (Ot−EtO_t - E_t). Under crossing survival curves, positive and negative deviations cancel out (Z→0Z \to 0), blinding the test to strong survival divergence. In contrast, SySurv's objective measures individual pointwise absolute deviations ∣Si(t)−Spop(t)∣|S_i(t) - S_{\text{pop}}(t)|, which are strictly positive and cannot cancel (formally analyzed in Appx. J; see also theoretical recovery guarantees in Appx. E). In the newly added Appx. J (Empirical Analysis, Table 2, Figure 9), we empirically validate this in an exhaustive search space: under crossing survival curves, logrank objective search collapses into background noise due to cancellation, whereas SySurv's objective preserves monotonic rank alignment and reliably recovers the true subgroup. Under delayed tail separation (Figure 10), logrank similarly degrades because late-emerging divergence is diluted by aggregate statistics, while SySurv's individual-first measure consistently succeeds.

    • Continuous optimization over discretization: The pre-discretization ablation in Appx. K.3 (Table 11) shows that continuous interval optimization avoids quantization artifacts inherent to fixed binning. Furthermore, in Appx. K.3 (Table 14), subgroup retrieval scales directly with the predictive accuracy of the underlying survival estimator, as formally bounded by Prop. E.2.

    In summary, SySurv’s measure restores sensitivity for crossing curves and delayed tail divergence where aggregate tests fail, while continuous optimization eliminates quantization and search bottlenecks faced by combinatorial methods. Both advances combined drive the empirical improvements.

  2. Core Methodological Contribution. You are right that SySurv’s methodological contribution cannot be reduced to a singular difference over existing methods. SySurv's methodological contribution is an integrated subgroup discovery framework: the differentiable exceptionality measure, continuous interval optimization, and decoupled individual survival regression each fill a distinct purpose. The individual survival divergence measure itself, as well as the unified end-to-end differentiable pipeline, represents the main methodological contribution. We have clarified this in the revised manuscript (Section 1).

  3. Figures. All figures for postoperative cancer, unemployment data, and HNSCC were discovered by SySurv on real-world datasets. We have updated figure captions throughout the manuscript to explicitly distinguish empirical findings from illustrative schematics:

    • Fig. 1: Real-world empirical survival curves discovered by SySurv on the postoperative cancer cohort (left) and unemployment benchmark data (right).

    • Fig. 2: Illustrative schematic depicting theoretical survival curve relationships.

    • Fig. 6: Real-world empirical Kaplan-Meier curves for subgroups discovered on the HNSCC cohorts.

Reviewer_FBHfOpenReview ↗
Rating
3
Confidence
2
Informativeness
2
Presentation
3
Soundness
3
Read review
Paper summary

In this study, a differentiable framework for survival subgroup discovery was proposed through subgroup exceptionality quantification and gradient-based optimization of feature intervals for interpretable rule learning. Experiments on both synthetic and real datasets demonstrate the effectiveness of the proposed method.

Critical strengths

The subgroup exceptionality is quantified through individual-level survival deviations to account for inter-individual heterogeneity. The rule learning is achieved through gradient-based optimization of soft feature intervals.

Critical weaknesses

The proposed method only focuses on subgroup discovery but not improve the characterization of individual-level survival profile.

Questions for authors
  1. As the subgroups are identified sequentially, what is the termination condition for the procedure? or how to determine the number of subgroups?

  2. The proposed method should also be compared with the survival clustering methods, which could also identify subgroups with different survival characteristics.

  3. For experiments on synthetic data, it would be helpful to see if the feature intervals identified by the model are consistent with that used for data generation. This could serve as the evaluation of model interpretability.

  4. Will the model generalize well on real cancer data? A cross-validation would be helpful. Also, it would be helpful to demonstrate the different biomarker profiles underlying different subgroups, for interpretability analysis.

1 comment

We thank the reviewer for their feedback.

SySurv builds directly on individual-level survival estimates: it takes them as input and summarizes them into interpretable rules for groups with exceptional survival. Better individual estimates directly improve subgroup discovery, as retrieval accuracy scales with the predictive performance of the underlying survival estimator (Appx. K.3, Table 14; Prop. E.2).

In response to your questions, we have updated the manuscript with: (i) a rule recovery analysis on synthetic data (Appx. K.1, under Rule Recovery), (ii) case study rule reliability validation (via bootstrap resampling) (Appx. K.4, Table 16), and (iii) a comprehensive biomarker hallmark mapping table (Appx. K.4, Table 17). We address the specific questions below:

  1. Termination Condition & Number of Subgroups. As with other sequential rule-learning frameworks, the number of exceptional subgroups is an exploratory quantity dictated by the dataset and size penalty γ\gamma. The sequential procedure terminates naturally when optimization yields trivial subgroups (empty sets or the full dataset) or previously discovered subgroups due to saturation of exceptional survival signals.

    Practitioners can either set an explicit target budget KK or stop once trivial or duplicate subgroups emerge.

  2. Survival Clustering vs. Subgroup Discovery. Survival clustering solves an unsupervised partitioning task (partitions could be exceptional), whereas subgroup discovery looks for what stands out and describes it. The two approaches pursue related but different objectives, and so direct comparison is not applicable.

  3. Rule Recovery. To evaluate whether gradient descent over continuous soft conditions recovers the true data-generating feature intervals, we added a bounding-box alignment analysis across repeated benchmark seeds to Appx. K.1 (under Rule Recovery). SySurv achieves a mean absolute boundary error of 0.037±0.0550.037 \pm 0.055 and a 1D interval Jaccard IoU of 0.870±0.1010.870 \pm 0.101 (overlap length divided by union span), underpinning the strong sample-level retrieval (F1=0.87±0.03F_1 = 0.87 \pm 0.03) reported in Table 11.

  4. Generalization on Cancer Data & Biomarker Profiles. Rule reliability validation on the case study cohort (200 bootstrap resamples; Appx. K.4, Table 16) confirms that discovered rules are robust to sampling variation: discovered survival curves replicate across resamples with minimal curve change under L1L^1 (median change ≤0.019\le 0.019 for better responders, with S6S_6 achieving exact 0.0000.000, and a median change ≤0.101\le 0.101 for poor responders; Table 16).

    Furthermore, Appx. K.4 (Table 17) provides the complete functional mapping of all 74 discovered biomarkers across canonical cancer hallmarks, confirming their biological interpretability.

Reviewer_S5cHOpenReview ↗
Rating
3
Confidence
2
Informativeness
3
Presentation
3
Soundness
2
Read review
Paper summary

The authors introduce SySurv, a new survival modeling method to identify clusters of samples with exceptional survival characteristics. In contrast to other methods, their approach requires less assumptions, e.g. they do not assume proportional hazards, which allows them to identify subgroups that differ not only in the survival rate, but also in the "shape" of the survival function over time. They evaluate on synthetic and real world data and showcase a case study on cancer data.

Critical strengths

Learning interpretable rules identifying subgroups with exceptional survival characteristics with differentiable optimization and without the proportional hazards assumption and pre-discretization is novel and interesting. I believe the method is well constructed and the methodology is convincing.

The interpretability aspects of their proposed method are particularly important for downstream applications in healthcare and beyond.

The real world out of sample evaluation, alongside the synthetic experiments and the case study is convincing.

Critical weaknesses

While the case study was performed well and the results appear reasonable, I'm unclear about the practical contribution of this case study. While it is good that the identified biomarkers appear to be largely consistent with existing medical understanding, it remains unclear whether SySurv discovers genuinely new insights. Furthermore, the case study does not include other methods, and it is not clear to me if any of the relaxed assumptions of SySurv translate into practical benefits in the case study.

The derived rules appear to be fairly complex even after pruning and are not externally validated. How trustworthy / reliable are these results really taking into account the small size of the datasets?

Claims about detrimental treatments and alternative treatment recommendations seem unjustified for an non-causal method. In general I feel the manuscript could be clearer about distinguishing causal and associative claims.

Questions for authors

How sensitive is the gradient-based rule learning to local minima?

How much do the discovered biomarkers overlap with those reported in Schmidt et al. (2020)? What genuinely new insights does SySurv provide?

Is external validation for any of the discovered rules in the case study feasible?

2 comments

We thank the reviewer for their feedback. We have updated the manuscript with several new analyses: (i) an evaluation of the baselines on the case study (Appx. K.4, Table 15, Figure 14), (ii) an evaluation of case study rule reliability using bootstraps (Appx. K.4, Table 16), (iii) a mapping between discovered biomarkers and their functions (Appx. K.4, Table 17), and (iv) emphasized the observational, non-causal scope of the case study (Section 4.3). We address the specific questions below:

  1. Case Study Contribution, Overlap, Insights & Competitors. SySurv’s practical contribution is that it automatically discovers multi-gene interactions without manual threshold tuning (e.g., the stratifications which Schmidt et al. had to do) that also works on small data.

    The overlap with Schmidt et al.: across both cohorts, 22 of the 74 pruned biomarkers (marked with † in Table 17, Appx. K.4), including 8/15 conditions in primary poor-responder S4S_4 (HIF1A, P4HA2, LDHA, PDK1, PGAM1, TPI1, ALDH3A1, MRGBP), belong directly to the established 15-, 26-, and 30-gene HNSCC hypoxia classifiers evaluated in Schmidt et al. (2020), confirming that SySurv recovers genuine biological signal.

    The new insight: in the postoperative cohort, SySurv identifies two small, high-risk subgroups (S5∗S_5^\ast, S7∗S_7^\ast) alongside zero-recurrence subgroups (S6S_6, S8S_8). Rather than relying on hypoxia genes alone, these rules (Tables 18–19) combine genes governing DNA repair (XRCC5, XRCC1), cell communication/tissue invasion (EPHA1, MAP2K2, MMP9, MMP13, LOX), and metabolism (CA9, ENO1, GPI), and select opposite expression ranges for poor vs. good responders (e.g., high MMP13∈[−1.9,1.7]\mathit{MMP13} \in [-1.9, 1.7] in poor-responder S5∗S_5^\ast vs. low MMP13∈[−10.4,−2.8]\mathit{MMP13} \in [-10.4, -2.8] in good-responder S6S_6).

    We run the baselines on the postoperative cohort for comparison (Appx. K.4, Table 15, Figure 14). While competitors either collapse into single-gene quantile bins with much weaker separation (EsmamDS), fragmented negative exclusions (RuleKit), or redundant subsets (FIBERS), SySurv identifies distinct poor-responder and better-responder subgroups with large survival shifts and high significance. Furthermore, in Appx. J and the newly added Empirical Analysis, Table 2, and Figures 9 and 10, we provide theoretical analysis and an empirical objective comparison showing why logrank baselines fail under crossing survival and delayed tail separation, which SySurv resolves.

  2. Rule Trustworthiness & Complexity. We address small sample sizes via permutation testing (Sec. 3.5, Appx. D). By permuting outcomes and rerunning SySurv on false datasets (broken covariate-outcome dependence) of the same size, we estimate the exceptionality distribution expected from false discoveries; smaller cohorts yield wider null distributions and face a stricter bar for significance. In addition, rule reliability validation (200 bootstrap resamples; Appx. K.4, Table 16) confirms that discovered survival curves replicate with minimal average survival curve change under L1L^1 (median change ≤0.019\le 0.019 for better responders, with S6S_6 achieving exact 0.0000.000, and a median change ≤0.101\le 0.101 for poor responders across resamples), achieving ≥99\ge 99% activation with stable subgroup sizes.

    Regarding rule complexity, multi-gene interactions and 20+ gene pathways are common in oncology (Schmidt et al., 2020; Eustace et al., 2013).

  3. Optimization Stability & Local Minima. SySurv mitigates optimization variance via deterministic initialization (rules initially span [−∞,∞]d[-\infty, \infty]^d) and full-batch gradient descent. While the objective is non-convex, SySurv achieves asymptotic recovery under a margin (Thm. E.7).

    As in any other gradient descent method, we cannot guarantee global convergence, but across cross-validation and benchmark runs (Appx. K.3, Tables 11 and 13), SySurv consistently achieves test F1≈0.87F_1 \approx 0.87–0.880.88, demonstrating reliable convergence.

  4. Feasibility of External Validation & Causal Framing. We agree on strictly distinguishing associative from causal claims and updated Section 4.3 to be more explicit.

    Because our rule thresholds are calibrated to a custom 158-gene NanoString panel absent from public RNA-seq repositories like TCGA, direct external cohort replication is not feasible. Instead, we evaluated rule reliability via bootstrap resampling (Appx. K.4, Table 16).

Thank you for the replies and additional experiments, you have largely addressed my concerns and I recommend acceptance of the paper.

From OpenReview, CC BY 4.0. Authors as signed there; shown unedited.

Related papers

Loading the map…

Discussion (0)

Sign in to comment.